157 related articles for article (PubMed ID: 25908517)
1. Discovery of novel indirubin-3'-monoxime derivatives as potent inhibitors against CDK2 and CDK9.
Yan L; Lai F; Chen X; Xiao Z
Bioorg Med Chem Lett; 2015 Jun; 25(11):2447-51. PubMed ID: 25908517
[TBL] [Abstract][Full Text] [Related]
2. 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity.
Choi SJ; Lee JE; Jeong SY; Im I; Lee SD; Lee EJ; Lee SK; Kwon SM; Ahn SG; Yoon JH; Han SY; Kim JI; Kim YC
J Med Chem; 2010 May; 53(9):3696-706. PubMed ID: 20361800
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel CDK inhibitors via scaffold hopping from CAN508.
Jing L; Tang Y; Xiao Z
Bioorg Med Chem Lett; 2018 May; 28(8):1386-1391. PubMed ID: 29550093
[TBL] [Abstract][Full Text] [Related]
4. 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity.
Wang S; Meades C; Wood G; Osnowski A; Anderson S; Yuill R; Thomas M; Mezna M; Jackson W; Midgley C; Griffiths G; Fleming I; Green S; McNae I; Wu SY; McInnes C; Zheleva D; Walkinshaw MD; Fischer PM
J Med Chem; 2004 Mar; 47(7):1662-75. PubMed ID: 15027857
[TBL] [Abstract][Full Text] [Related]
5. Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex.
Echalier A; Bettayeb K; Ferandin Y; Lozach O; Clément M; Valette A; Liger F; Marquet B; Morris JC; Endicott JA; Joseph B; Meijer L
J Med Chem; 2008 Feb; 51(4):737-51. PubMed ID: 18232649
[TBL] [Abstract][Full Text] [Related]
6. Scaffold Hopping Approach to a New Series of Pyridine Derivatives as Potent Inhibitors of CDK2.
Xu X; Yao Q
Arch Pharm (Weinheim); 2016 Mar; 349(3):224-31. PubMed ID: 26871934
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of indirubin analogues as phosphorylase kinase inhibitors.
Begum J; Skamnaki VT; Moffatt C; Bischler N; Sarrou J; Skaltsounis AL; Leonidas DD; Oikonomakos NG; Hayes JM
J Mol Graph Model; 2015 Sep; 61():231-42. PubMed ID: 26364215
[TBL] [Abstract][Full Text] [Related]
8. Anti-mitotic properties of indirubin-3'-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest.
Damiens E; Baratte B; Marie D; Eisenbrand G; Meijer L
Oncogene; 2001 Jun; 20(29):3786-97. PubMed ID: 11439342
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/Cyclin E inhibitors.
Baltus CB; Jorda R; Marot C; Berka K; Bazgier V; Kryštof V; Prié G; Viaud-Massuard MC
Eur J Med Chem; 2016 Jan; 108():701-719. PubMed ID: 26741853
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells.
Marko D; Schätzle S; Friedel A; Genzlinger A; Zankl H; Meijer L; Eisenbrand G
Br J Cancer; 2001 Jan; 84(2):283-9. PubMed ID: 11161389
[TBL] [Abstract][Full Text] [Related]
11. Indirubin 3'-(O-oxiran-2-ylmethyl)oxime: a novel anticancer agent.
Ichimaru Y; Saito H; Uchiyama T; Metori K; Tabata K; Suzuki T; Miyairi S
Bioorg Med Chem Lett; 2015 Apr; 25(7):1403-6. PubMed ID: 25765906
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and structure-activity relationships of novel indirubin derivatives as potent anti-proliferative agents with CDK2 inhibitory activities.
Moon MJ; Lee SK; Lee JW; Song WK; Kim SW; Kim JI; Cho C; Choi SJ; Kim YC
Bioorg Med Chem; 2006 Jan; 14(1):237-46. PubMed ID: 16182537
[TBL] [Abstract][Full Text] [Related]
13. Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model.
Singh U; Chashoo G; Khan SU; Mahajan P; Nargotra A; Mahajan G; Singh A; Sharma A; Mintoo MJ; Guru SK; Aruri H; Thatikonda T; Sahu P; Chibber P; Kumar V; Mir SA; Bharate SS; Madishetti S; Nandi U; Singh G; Mondhe DM; Bhushan S; Malik F; Mignani S; Vishwakarma RA; Singh PP
J Med Chem; 2017 Dec; 60(23):9470-9489. PubMed ID: 29144137
[TBL] [Abstract][Full Text] [Related]
14. Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity.
Xu J; Li H; Wang X; Huang J; Li S; Liu C; Dong R; Zhu G; Duan C; Jiang F; Zhang Y; Zhu Y; Zhang T; Chen Y; Tang W; Lu T
Eur J Med Chem; 2020 Aug; 200():112424. PubMed ID: 32447197
[TBL] [Abstract][Full Text] [Related]
15. Indirubin-3'-monoxime inhibits autophosphorylation of FGFR1 and stimulates ERK1/2 activity via p38 MAPK.
Zhen Y; Sørensen V; Jin Y; Suo Z; Wiedłocha A
Oncogene; 2007 Sep; 26(44):6372-85. PubMed ID: 17533378
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel 5-fluoro-
Gao J; Fang C; Xiao Z; Huang L; Chen CH; Wang LT; Lee KH
Medchemcomm; 2015 Mar; 6(3):444-454. PubMed ID: 25914804
[TBL] [Abstract][Full Text] [Related]
17. Targeting of CDK9 with indirubin 3'-monoxime safely and durably reduces HIV viremia in chronically infected humanized mice.
Medina-Moreno S; Dowling TC; Zapata JC; Le NM; Sausville E; Bryant J; Redfield RR; Heredia A
PLoS One; 2017; 12(8):e0183425. PubMed ID: 28817720
[TBL] [Abstract][Full Text] [Related]
18. Indirubin-3'-monoxime, a CDK inhibitor induces growth inhibition and apoptosis-independent up-regulation of survivin in transitional cell cancer.
Perabo FG; Frössler C; Landwehrs G; Schmidt DH; von Rücker A; Wirger A; Müller SC
Anticancer Res; 2006; 26(3A):2129-35. PubMed ID: 16827155
[TBL] [Abstract][Full Text] [Related]
19. A convenient synthesis and molecular modeling study of novel purine and pyrimidine derivatives as CDK2/cyclin A3 inhibitors.
Elgazwy AS; Ismail NS; Elzahabi HS
Bioorg Med Chem; 2010 Nov; 18(21):7639-50. PubMed ID: 20851615
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, biological evaluation, and molecular docking studies of N-((1,3-diphenyl-1H-pyrazol-4-yl)methyl)aniline derivatives as novel anticancer agents.
Huang XF; Lu X; Zhang Y; Song GQ; He QL; Li QS; Yang XH; Wei Y; Zhu HL
Bioorg Med Chem; 2012 Aug; 20(16):4895-900. PubMed ID: 22819191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
